<DOC>
	<DOCNO>NCT03035370</DOCNO>
	<brief_summary>The study Phase I , first human , monocenter study , aim assess safety immunogenicity genetically detoxify pertussis toxin ( PT ) administer via cutaneous route Viaskin patch healthy volunteer 2 different dos 25 mcg 50 mcg PT protein compare Viaskin placebo . Two cohort 30 subject successively enrol . Safety product assess throughout 10-week study immunogenicity assess regular interval collection blood sample immunological analysis . Four week second Viaskin application ( Day 42 study ) , subject receive dose diphtheria-tetanus-pertussis vaccine ( BoostrixÂ® dTpa ) ensure optimal recall immunity pertussis .</brief_summary>
	<brief_title>Viaskin Pertussis Vaccine Trial</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Has provide write informed consent enrollment ; Adult male female , age 18 40 year ( inclusive ) time enrollment ; Nonpregnant , nonlactating female ; Free clinically significant health problem , determine pertinent medical history clinical examination study screen ; With documented history pertussis immunization ( least 4 dos ) ; Women childbearing potential negative pregnancy test entry ; Females childbearing potential willing use effective method contraception . Prior dTpa immunization within last 10 year prior dT immunization within last 2 year , investigational vaccine likely impact interpretation trial data ; Suspected confirm pertussis infection within last 10 year document pertussis infection household member within last 10 year ; Receipt license vaccine within 14 day plan study immunization ( 30 day live vaccine ) ongoing participation another clinical interventional trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Epicutaneous ImmunoTherapy ( EPIT )</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Viaskin PT</keyword>
</DOC>